報價延遲最少15分鐘:2025/06/12 20:11 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.73 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.70/-0.75
|
|
企業價值
3.64M
|
| 資產負債 |
|
每股賬面淨值
5.83
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
144.00K
|
|
每股收益
0.25
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/12 20:11 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. |